Breast Cancer | Norton Healthcare

Indication: Breast Cancer

Elacestrant Monotherapy Vs. Standard Of Care For The Treatment Of Patients With Er+/Her2- Advanced Breast Cancer Following Cdk4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial (EMERALD)

HER2 Negitive

Line of Therapy: 2nd or 3rd Line

Drug Study

Principal Investigator: Jeffrey Hargis, M.D.
Norton Cancer Institute

Sponsor: Radius Pharmaceuticals, Inc.

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.